XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.25.2

INVENTORIES | 6 Months Ended
--- | ---
Jun. 30, 2025
INVENTORIES [Abstract] |
INVENTORIES | 3. INVENTORIES The following table provides the components of inventories:
|  | June 30, 2025 |  |  |  | December 31, 2024 |
|  | (In thousands) |
Raw materials | $ | 100,373 |  |  | $ | 60,473 |
Work-in-process |  | 43,173 |  |  |  | 61,641 |
Finished goods |  | 47,918 |  |  |  | 48,121 |
Total inventories, net | $ | 191,464 |  |  | $ | 170,235 |
Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit. Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company’s immunoglobulin products. Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available for commercial sale, as well as plasma collected at the Company’s plasma collection centers that is expected to be sold to third-party customers.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration